First filed December 23, 2020, Updated July 2022; Recruiting
CATEGORIES: General SLE
The purpose of this Phase 2 study is to evaluate the efficacy and safety of efavaleukin alfa in subjects with active SLE.
This study is being offered at 20 LuCIN sites – institutions that are members of the Lupus Clinical Investigators Network managed by Lupus Therapeutics, an affiliate of the Lupus Research Alliance.
To Learn More Contact
Amgen Call Center at 866-572-6436 or email firstname.lastname@example.org
ClinicalTrials.gov identifier (NCT number): NCT04680637